Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 17/20 | 0.65 |
| ▸ | ADRA2B | P18089 | 17/20 | 0.65 |
| ▸ | ADRA2C | P18825 | 17/20 | 0.65 |
| ▸ | ADRA1D | P25100 | 3/20 | 0.65 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.65 |
| ▸ | ADRA1B | P35368 | 3/20 | 0.65 |
| ▸ | PTGIR | P43119 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7091961 | 0.89 | ADRA2A (0.65) | ADRA2AADRA2BADRA2CADRA1DADRA1A | |
| SCHEMBL679239 | 0.79 | ADRA2A (1.00) | ADRA2AADRA2BADRA2CADRA1DADRA1A | |
| SCHEMBL6764478 | 0.75 | NISCH (0.58) | ADRA2AADRA2BADRA2CADRA1DADRA1A | |
| SCHEMBL7027287 | 0.75 | ADRA2A (0.50) | ADRA2AADRA2BADRA2CADRA1DADRA1A | |
| SCHEMBL7027298 | 0.75 | ADRA2A (0.50) | ADRA2AADRA2BADRA2CADRA1DADRA1A | |
| SCHEMBL7027314 | 0.75 | ADRA2A (0.51) | ADRA2AADRA2BADRA2CADRA1DADRA1A | |
| SCHEMBL7033369 | 0.75 | ADRA2A (0.58) | ADRA2AADRA2BADRA2CADRA1DADRA1A | |
| SCHEMBL7028922 | 0.75 | ADRA2A (0.51) | ADRA2AADRA2BADRA2CADRA1DADRA1A | |
| SCHEMBL7032878 | 0.75 | ADRA2A (0.51) | ADRA2AADRA2BADRA2CADRA1DADRA1A | |
| SCHEMBL7027639 | 0.75 | ADRA2C (0.51) | ADRA2AADRA2BADRA2CADRA1DADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0780127-A1 | A nasal spray containing a steroid and a antihistamine | THE PROCTER & GAMBLE COMPANY (US) | 1997-06-25 | — | — | EP | claimed |
| EP-2525793-B1 | Alpha-2 adrenergic agonist having long duration of intraocular pressure-lowering effect | ALLERGAN INC (US) | 2018-09-05 | — | — | EP | disclosed |
| EP-1953146-B1 | METHODS OF MAKING 6-[(4,5-DIHYDRO-1H-IMIDAZOL-2-YL) AMINO-]-7-METHYL-1H-BENZIMIDAZOLE-4-CARBONITRILE AND ITS PREFERRED SALT FORM | UNIV NEBRASKA (US) | 2014-04-30 | — | — | EP | disclosed |
| EP-1594862-B1 | METHODS OF MAKING 6-[ (4,5-DIHYDRO-1H-IMIDAZOL-2-YL)AMINO-] -7-METHYL-1H-BENZIMIDAZOLE-4-CARBONITRILE AND ITS PREFERRED SALT FORM | UNIV NEBRASKA (US) | 2008-11-19 | — | — | EP | disclosed |
| EP-1953146-A1 | Methods of making 6-[(4,5-Dihydro-1H-imidazol-2-yl) amino-]-7-methyl-1H-benzimidazole-4-carbonitrile and its preferred salt form | The Board of Regents of the University of Nebraska (US) | 2008-08-06 | — | — | EP | disclosed |
| US-7304084-B2 | 6-[(4,5-Dihydro-1H-imidazol-2-yl)amino]-7-methyl-1H-benzimidazole-4-carbonitrile and its preferred salt | THE BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA (US) | 2007-12-04 | — | — | US | disclosed |
| US-20060122248-A1 | Methods of making 6-[(4,5-dihydro-1H-imidazol-2-yl)amino-]-7-methyl-1H-benzimidazole-4-carbonitrile and its preferred salt form | BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA | 2006-06-08 | — | — | US | disclosed |
| EP-1594862-A1 | METHODS OF MAKING 6- (4,5-DIHYDRO-1H-IMIDAZOL-2-YL)AMINO-&rs qb;-7-METHYL-1H-BENZIMIDAZOLE-4-CARBONITRILE AND ITS PREFERRED SALT FORM | The Board of Regents of the University of Nebraska (US) | 2005-11-16 | — | — | EP | disclosed |
| WO-2004074279-A1 | METHODS OF MAKING 6-[(4,5-DIHYDRO-1H-IMIDAZOL-2-YL)AMINO-]-7-METHYL-1H-BENZIMIDAZOLE-4-CARBONITRILE AND ITS PREFERRED SALT FORM | THE BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA (US) | 2004-09-02 | — | — | WO | disclosed |
| US-20040167194-A1 | Methods of making 6-[(4,5-Dihydro-1H-imidazol-2-yl)amino-]-7-methyl-1H-benzimidazole-4-carbonitrile and its preferred salt form | THE BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA | 2004-08-26 | — | — | US | disclosed |
| CN-1137794-A | 5-(2-imidazolinylamino) benzimidazole derivatives, their preparation and their use as alpha-2 adrenoceptor agonists | PROCTER & GAMBLE (US) | 1996-12-11 | — | — | CN | disclosed |
| EP-0736022-A1 | 5-(2-IMIDAZOLINYLAMINO)BENZIMIDAZOLE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS ALPHA-2 ADRENOCEPTOR AGONISTS | THE PROCTER & GAMBLE COMPANY (US) | 1996-10-09 | — | — | EP | disclosed |
| EP-0736022-A1 | 5-(2-IMIDAZOLINYLAMINO)BENZIMIDAZOLE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS ALPHA-2 ADRENOCEPTOR AGONISTS | THE PROCTER & GAMBLE COMPANY (US) | 1996-10-09 | — | — | EP | disclosed |
| US-5541210-A | ANALGESICS, ANTIINFLAMMATORY AGENTS, ANTIHISTAMINES OR COUGH MEDICINE | THE PROCTER & GAMBLE COMPANY (US) | 1996-07-30 | — | — | US | disclosed |
| US-5541210-A | ANALGESICS, ANTIINFLAMMATORY AGENTS, ANTIHISTAMINES OR COUGH MEDICINE | THE PROCTER & GAMBLE COMPANY (US) | 1996-07-30 | — | — | US | disclosed |
| WO-1996004270-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 1996-02-15 | — | — | WO | disclosed |
| US-5478858-A | Respiratory system disorders, gastrointestinal disorders | THE PROCTER & GAMBLE COMPANY (US) | 1995-12-26 | — | — | US | disclosed |
| US-5478858-A | Respiratory system disorders, gastrointestinal disorders | THE PROCTER & GAMBLE COMPANY (US) | 1995-12-26 | — | — | US | disclosed |
| WO-1995016685-A1 | 5-(2-IMIDAZOLINYLAMINO)BENZIMIDAZOLE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS ALPHA-2 ADRENOCEPTOR AGONISTS | THE PROCTER & GAMBLE COMPANY (US) | 1995-06-22 | — | — | WO | disclosed |
| WO-1995016685-A1 | 5-(2-IMIDAZOLINYLAMINO)BENZIMIDAZOLE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS ALPHA-2 ADRENOCEPTOR AGONISTS | THE PROCTER & GAMBLE COMPANY (US) | 1995-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040167194-A1 | Methods of making 6-[(4,5-Dihydro-1H-imidazol-2-yl)amino-]-7-methyl-1H-benzimidazole-4-carbonitrile and its preferred salt form | AGTR2, ALDH1A2, REN | ADRA2A 39/4885ADRA2B 138/4885ADRA2C 77/4885 |
| US-20060122248-A1 | Methods of making 6-[(4,5-dihydro-1H-imidazol-2-yl)amino-]-7-methyl-1H-benzimidazole-4-carbonitrile and its preferred salt form | AGTR2, ALDH1A2, REN | ADRA2A 38/4885ADRA2B 143/4885ADRA2C 75/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.